nebulized epinephrine and nebulized albuterol — Competitive Intelligence Brief

nebulized epinephrine and nebulized albuterol (nebulized epinephrine and nebulized albuterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adrenergic agonist combination. Area: Pulmonology / Respiratory.

marketed Adrenergic agonist combination Alpha-adrenergic receptors, Beta-2 adrenergic receptors Pulmonology / Respiratory Small molecule

Target snapshot

nebulized epinephrine and nebulized albuterol (nebulized epinephrine and nebulized albuterol) — Rambam Health Care Campus. Nebulized epinephrine and albuterol work synergistically as bronchodilators and decongestants to rapidly open airways and reduce airway inflammation and edema.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nebulized epinephrine and nebulized albuterol TARGET	nebulized epinephrine and nebulized albuterol	Rambam Health Care Campus	marketed	Adrenergic agonist combination	Alpha-adrenergic receptors, Beta-2 adrenergic receptors
Solifenacin + Mirabegron	Solifenacin + Mirabegron	University of Aarhus	marketed	Antimuscarinic + Beta-3 adrenergic agonist combination	M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)
Ropivacaine + Dexmedetomidine	Ropivacaine + Dexmedetomidine	Sahiwal medical college sahiwal	marketed	Local anesthetic + alpha-2 adrenergic agonist combination	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
Brinzolamide/Brimonidine FC	Brinzolamide/Brimonidine FC	University Hospital of Patras	marketed	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor
tolterodine , mirabegron	tolterodine , mirabegron	Far Eastern Memorial Hospital	marketed	Antimuscarinic and beta-3 adrenergic agonist combination	Muscarinic M3 receptor and beta-3 adrenergic receptor
Sufentanil and dexmedetomidine	Sufentanil and dexmedetomidine	Obstetrics & Gynecology Hospital of Fudan University	marketed	Opioid agonist and alpha-2 adrenergic agonist combination	Mu opioid receptor and alpha-2 adrenergic receptor
Aceclidine+Brimonidine combination ophthalmic solution	Aceclidine+Brimonidine combination ophthalmic solution	LENZ Therapeutics, Inc	phase 3	Muscarinic agonist + alpha-2 adrenergic agonist combination	Muscarinic acetylcholine receptors; alpha-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adrenergic agonist combination class)

1. Rambam Health Care Campus · 1 drug in this class